Johnson & Johnson Advances Spin-Off and Sale in Parallel as Orthopedics Business Valued at Nearly $20 Billion
Apollo Global Management is in talks to acquire Johnson & Johnson's (JNJ) orthopedics unit DePuy Synthes for nearly $20 billion. JNJ may also spin off the unit, which generated $9.3 billion in 2025 revenue. The company is focusing on faster-growing healthcare segments, aiming for $100 billion in annual revenue. JNJ's CFO confirmed the spin-off process is underway, with updates expected by mid-2026.
How this was made
The 30-second read
Why it matters
The announced talks with Apollo introduce a concrete potential buyer and a $20 B price tag, creating immediate market relevance.
Market read
A high‑value M&A discussion involving a major US health‑care company could move JNJ shares and influence sector sentiment.
What to watch
Pending litigation over hip‑replacement devices could depress valuation.
Background
Johnson & Johnson has been exploring strategic options for its DePuy Synthes orthopedics business, including a possible spin‑off within 18‑24 months.
Ticker impact
Apollo Global Management is in talks to acquire JNJ's DePuy Synthes orthopedics unit, valued at nearly $20 billion, with possible spin‑off options.
Short‑term upside risk if deal terms improve; downside if negotiations stall.
Large $20 B valuation and multiple strategic paths create material market uncertainty.
Market effects
May trigger further consolidation in med‑tech and orthopedics sectors.
U.S. healthcare investors could re‑price exposure to JNJ's med‑tech segment.
Highlights private‑equity appetite for large‑cap health assets worldwide.
Counterpoint
Deal could be delayed or fall apart, leaving JNJ to retain a low‑growth unit.
Key entities
- CompanyJohnson & Johnson
US‑listed healthcare conglomerate (ticker JNJ).
- Private‑Equity FirmApollo Global Management
Potential acquirer of DePuy Synthes.
